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Approximately 30% of the general population suffers from insomnia. Given that insomnia
causes many problems, amelioration of the symptoms is crucial. Recently, we found that
a non-essential amino acid, glycine subjectively and objectively improves sleep quality in
humanswho have difﬁculty sleeping.We evaluated the effects of glycine on daytime sleepi-
ness, fatigue, and performances in sleep-restricted healthy subjects. Sleep was restricted
to 25% less than the usual sleep time for three consecutive nights. Before bedtime, 3 g
of glycine or placebo were ingested, sleepiness, and fatigue were evaluated using the
visual analog scale (VAS) and a questionnaire, and performance were estimated by per-
sonal computer (PC) performance test program on the following day. In subjects given
glycine, the VAS data showed a signiﬁcant reduction in fatigue and a tendency toward
reduced sleepiness. These observations were also found via the questionnaire, indicating
that glycine improves daytime sleepiness and fatigue induced by acute sleep restriction.
PC performance test revealed signiﬁcant improvement in psychomotor vigilance test. We
alsomeasured plasmamelatonin and the expression of circadian-modulated genes expres-
sion in the rat suprachiasmatic nucleus (SCN) to evaluate the effects of glycine on circadian
rhythms. Glycine did not show signiﬁcant effects on plasma melatonin concentrations dur-
ing either the dark or light period. Moreover, the expression levels of clock genes such as
Bmal1 and Per2 remained unchanged. However, we observed a glycine-induced increase
in the neuropeptides arginine vasopressin and vasoactive intestinal polypeptide in the light
period. Although no alterations in the circadian clock itself were observed, our results indi-
cate that glycine modulated SCN function. Thus, glycine modulates certain neuropeptides
in the SCN and this phenomenon may indirectly contribute to improving the occasional
sleepiness and fatigue induced by sleep restriction.
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INTRODUCTION
Approximately 30% of the general population suffer from symp-
toms of insomnia (Ohayon, 2002). Insomnia-induced problems
include cognitive inefﬁciency, sleepiness,mood disruptions (Zam-
mit, 1988), impaired attention, andmemory deﬁcits (Hauri, 1997).
Thus, treatment of insomnia is critical. To treat the symptoms,
hypnotics are often used by those suffering from insomnia. More-
over, some natural herb extracts, such as chamomile (Shinomiya
et al., 2005) and valerian (Fernandez-San-Martin et al., 2010) have
been used to cure insomnia.
Recently, we found that glycine subjectively and objectively
improved sleep quality in humans who suffered from repeated
sleep complaints (Inagawa et al., 2006a; Yamadera et al., 2007).
Glycine is a non-essential amino acid, and mammals can pro-
duce sufﬁcient amounts of it via de novo synthesis. In humans,
approximately 45 g of endogenous glycine is synthesized (Gerso-
vitz et al., 1980), and 3–5 g of glycine is ingested from the daily diet.
In both the peripheral and central nervous system, glycine acts
as an inhibitory neurotransmitter via glycine receptors (Rajen-
dra et al., 1997). Conversely, this amino acid also acts as an
excitatory co-agonist via theN -methyl-d-aspartate subtypeof glu-
tamate receptors (NMDARs; Johnson and Ascher, 1987; Leeson
and Iversen, 1994). Glycine has anti-inﬂammatory effects during
ischemia, injury, and transplantation (Zhong et al., 2003). More-
over, glycine is known to attenuate the increase in fatty acids in
rats fed on a high sucrose diet (El Haﬁdi et al., 2004).
In urban populations, most individuals experience restricted
sleep. This is especially true for ofﬁce workers in large cities, who
are prone to restricted sleep periods during the week. During
partial sleep restriction, daytime sleepiness and fatigue have been
shown to increase, and daytime performance has been shown to
be impaired (Dinges et al., 1997; Belenky et al., 2003; Van Dongen
et al., 2003); these parameters can also be indicative of sleep qual-
ity. Taken together, improving sleep quality during sleep-restricted
periods would ameliorate daytime sleepiness and fatigue. We
investigated the use of glycine to improve sleep quality under par-
tially sleep-restricted conditions using daytime sleepiness, fatigue,
and performance as measurements.
To investigate the mechanisms by which glycine improves sleep,
we assessed the permeability of the blood–brain barrier to glycine
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in a rat model (Kawai et al., 2012). The results indicated that
ingested glycine passively diffuses across the blood–brain barrier
by non-speciﬁc transportation. Furthermore, glycine improves
sleep in rats by decreasing core body temperature and increasing
vasodilatation (Kawai et al., 2009; Bannai and Kawai, 2011). The
suprachiasmatic nucleus (SCN) is necessary for glycine-induced
hypothermia and vasodilatation because ingested glycine primar-
ily acts on the NMDARs in the SCN. This mechanism may result
in an improvement in sleep quality. Although glycine has been
shown to improve sleep quality in humans and rats (Inagawa
et al., 2006a; Yamadera et al., 2007; Kawai et al., 2009; Bannai and
Kawai, 2011), the relationship between glycine ingestion and the
circadian clock remains unknown. The relationship between the
clock gene and sleep are well known. For example, Per2 mutation
results in advanced sleep phase syndrome (Toh et al., 2001; Xu
et al., 2005), and Dec2 mutation causes short sleep phenotypes in
humans (He et al., 2009). Melatonin is secreted by the pineal gland
and circulates throughout the body. Melatonin concentrations are
high during the dark period in all species, regardless of diurnal
or nocturnal activity (Turek and Gillette, 2004; Arendt, 2005).
Therefore, the timing of melatonin secretion is associated with
circadian rhythms. The SCN, where many types of neuropeptides
and clock genes are localized, is known as the circadian pace-
maker site (Morin and Allen, 2006). We investigated the effects of
glycine on melatonin concentrations in blood and the expression
of neuropeptides and clock genes in the SCN.
MATERIALS AND METHODS
HUMAN STUDY
Participants
The study protocol was approved by the Institutional Review
Board of Ajinomoto Co., Inc. All of the participants enrolled in
this study provided their written informed consent after receiv-
ing an explanation of the study procedure and the potential risks
of the study. All of the procedures were carried out in accor-
dance with Good Clinical Practice, the Helsinki Declaration, and
related laws.
Ten healthy, male volunteers (30–61 years of age; average,
41.4 years) who were employed at Ajinomoto Co., Inc. as full-
time weekday workers participated. The subjects had good general
health as determined by medical history and a medical examina-
tion. All of the participants were free of sleep disorders. To obtain
background information on the sleep characteristics of the par-
ticipants, the Pittsburgh Sleep Quality Index (PSQI) was used to
evaluate their sleep patterns over the previousmonth (Buysse et al.,
1989; Smyth, 1999; Doi et al., 2000). Furthermore, before the test
period, the subjects were required to record a sleep log and ﬁll out
the visual analog scale (VAS) upon waking for 5weekdays for the
purposes of adaptation and acquiring baseline data. Substances
such as alcohol, vitamin B12, melatonin, and other medication
that may affect natural sleep were prohibited, and the partici-
pants’ lifestyle patterns (except sleep) were kept constant during
the test period. Among the 10 participants, 1 dropped out, and
another 2 who took medication for inﬂuenza and a pollen allergy
during the experimental period were excluded. Statistical analysis
was performed on seven subjects (average, 40.6 years; PSQI score,
4.7± 0.47).
Methods
This was a randomized single-blinded crossover trial. During the
adaptation period (the ﬁrst three consecutive nights), the partic-
ipants spent the usual time in bed (TIB; average, 7.3 h). During
the experimental period, each participant took ﬂavored glycine
(3 g) or ﬂavored placebo (a reduced form of malt sugar with the
same ﬂavor as glycine) 30min before bedtime and their TIB was
restricted to 25% less than usual (average, 5.5 h) for three con-
secutive nights. Daytime naps were not permitted, and sleep was
limited by delaying going to bed. Sleep duration was monitored
by sleep logs.
On the ﬁrst and last days of the experimental period (days 1
and 3) at 10:00, 14:00, and 18:00, the participants rated their own
daytime sleepiness, fatigue, and performance using the VAS. In
addition to the VAS, subjective daytime sleepiness and fatigue was
recorded using a questionnaire for fatigue complaints (Jikaku-
sho Shirabe) established by Japan Society for Occupational Health
(Sasaki and Matsumoto, 2005). This questionnaire consisted of 25
items that included ﬁve factors (Factors I–V) drawn from the fac-
tor analysis and 5 subordinate items for each of those ﬁve factors.
These ﬁve factors were as follows: feeling of drowsiness (Factor I),
feeling of instability (Factor II), feeling of uneasiness (Factor III),
feeling of local pain or dullness (Factor IV), and feeling of eyestrain
(Factor V). Responses were measured on a ﬁve point rating scale
ranging from “disagree completely” (1 point) to “agree strongly”
(5 points). Performance was estimated by a sequence of the com-
mercial test program“Performance Test Program”(NoruPro Light
Systems, Inc.,Tokyo, Japan). Test batterywas composedof four dif-
ferent performance tasks and an instruction for each session was
shown on the monitor at the beginning of the session. The ﬁrst
task was 3-min simple reaction test, in which participants were
required to click as soon as possible when a symbol was displayed
on the screen with a randomized interval (2–3 s). The second task
was 4-min psychomotor vigilance test, where one of three symbols
was randomly presented with a randomized interval (1.8–3 s), and
the examinee was required to respond if the symbol was same as
the target one. The third task was 3-min memory recognition task,
where the test stimuli (a digit or an alphabet) was presented with
an interval of 1.5 s, and the examinee had to select right-click or
left-click according to whether the stimuli was the same as the
target (a certain digit or alphabet). The last task was number addi-
tion test, in which examinee was required to input the sum of two
numbers of two digits.
After 7–14 recovery nights, the participants underwent another
sequence of trials. During this time, the participants were given the
ﬂavored test substance that had not been administered previously.
Statistical analysis
Data are expressed as the mean± SE. A two-way analysis of vari-
ance (ANOVA) was used to evaluate the effects of glycine. Post hoc
analyses were conducted using the Holm–Sidak method when
signiﬁcant differences (p< 0.05) were observed.
RAT STUDY
Animals
The rat experimental protocol was reviewed and approved by
the Animal Care Committee of Ajinomoto. Male Wister rats
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(Charles River Japan, Yokohama, Japan) were purchased and
housed individually in cages made of stainless steel wire. Rodent
chow (CRF-1, Oriental Yeast, Tokyo, Japan) and tap water were
available without restriction. The animal room was maintained
at a constant temperature (23 ± 2˚C) and humidity (55± 10%),
with a 12-h light/dark cycle (lights on 7.00–19.00).
At 9.00 (light period) or 21.00 (dark period), 2 g/kg glycine or
vehicle (distilled water) was orally administered via gavage. The
animals were anesthetized and sacriﬁced to collect blood and the
brain 2 h later. The SCN was punched out from brain tissues for
analysis.
Melatonin assay and quantiﬁcation of mRNA expression
The melatonin concentrations present in plasma samples were
determined by radioimmunoassay as described previously (Naka-
hara et al., 2002). The radioiodinated and non-radioactive mela-
tonin used as standards were purchased from New England
Nuclear and Sigma, respectively. The rabbit anti-melatonin serum
(HAC-AA92-03RBP86)was supplied byDr.Wakabayashi (Gunma
University, Japan).
To quantify the mRNA expression of arginine vasopressin
(AVP) and vasoactive intestinal polypeptide (VIP), total RNA was
isolated from the SCN using the RNeasy Micro Kit (QIAGEN)
and used for reverse transcription reactions with SuperScript™II
RNaseHReverse Transcriptase (Invitrogen) according to theman-
ufacturer’s instructions. Quantitative PCR was performed using
an ABI PRISM 7900HT (Applied Biosystems) with SYBR green
ﬂuorescence detection. Relative expression levels were normalized
to the 18S expression levels in the same sample. The following
primer sequences were used to detect the mRNA of each clock
gene or neuropeptide:
18S Forward: CGCGGTTCTATTTTGTTGGTTTTCG
Reverse: CTGATCGTCTTCGAACCTCCGACTT
Bmal1 Forward: AACCCGTGGACCAAGGAAGT
Reverse: GTGAGCTGTGGGAAGGTTGG
Per2 Forward: CATGGCCAGTGTGCAGAGAG
Reverse: GAGGCCACCAAACAGACAGG
AVP Forward: TCGCCATGATGCTCAACACT
Reverse: GCCTCCTCTTGGGCAGTTCT
VIP Forward: GTTCCTGGCGATCCTGACAC
Reverse: AGGCCAGCGACTGTGAGAAC
Statistical analysis
The data are expressed as the mean± SE. A two-way ANOVA was
used to evaluate the effects of glycine. When a signiﬁcant differ-
ence (p< 0.05) was observed, post hoc analyses were conducted
using the Holm–Sidak method.
RESULTS
HUMAN STUDY
Sleepiness and fatigue
Data from the VAS test showed signiﬁcant effects on fatigue on
day 1 (p = 0.022); however, no signiﬁcant effects were observed
Table 1 | Results and statistics forVAS and the questionnaire for fatigue complaints on day 1.
Results Statistics
Placebo Glycine Treatment Treatment × time
10:00 14:00 18:00 10:00 14:00 18:00 F 1,6 p F 2,12 p
VAS
Sleepiness; Sleepy:
100 – alert: 0
48.1 (5.65) 52.9 (10.51) 51 (6.97) 32.7 (7.94) 36 (6.78) 45.6 (8.71) 3.82 0.098 0.26 0.774
Fatigue; Extremely
fatigued:
100 – vigorous: 0
48.3 (4.97) 53.1 (6.2) 59.6 (8.14) 33.6 (4.6) 35.4 (8.62) 51 (9.73) 9.36 0.022 0.48 0.628
QUESTIONNAIRE FOR FATIGUE COMPLAINTS
Factor
I – drowsiness
11.7 (1.46) 11.7 (1.55) 10.1 (1.79) 8 (0.79) 7.4 (0.84) 8.9 (0.99) 5.03 0.066 0.38 0.691
Factor II – instability 9.3 (0.84) 9.6 (1.32) 8 (1.13) 6.6 (0.43) 7 (1) 7.6 (1.32) 4.77 0.072 3.35 0.07
Factor
III – uneasiness
9 (0.98) 8.9 (1.18) 9 (2.36) 7.6 (0.43) 7.4 (0.81) 8.4 (1.02) 1.55 0.259 0.25 0.78
Factor IV – local pain
or dullness
7.7 (0.64) 7.4 (0.53) 7.1 (0.74) 6.6 (0.57) 6.4 (0.53) 6.7 (0.47) 3.16 0.125 0.51 0.611
Factor V – eyestrains 9.4 (1.51) 8.9 (1.53) 9.6 (1.17) 7.4 (1.09) 8 (1.18) 8.4 (1.43) 4.41 0.081 0.61 0.559
Total score;
extremely fatigued:
125 – vigorous: 25
47 (4.24) 46.1 (4.93) 43.7 (6.17) 36.1 (1.75) 36.3 (3.21) 40 (4.21) 4.44 0.08 1.2 0.334
In the questionnaire for fatigue complaints, larger scores reveal the worth statement for each factor. The data are expressed as the mean (SE). A two-way ANOVA
was used to test statistical signiﬁcance.
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for sleepiness (p = 0.098, Table 1). Post hoc analysis revealed a
signiﬁcant improvement in fatigue at 14:00 (p = 0.022). Table 1
also shows the results of the questionnaire for fatigue complaints.
No signiﬁcant effects were observed between the placebo and
glycine treatment groups for any measurement; however, some
of the questions showed a tendency toward differences in drowsi-
ness (p = 0.066), instability (p = 0.072), and eyestrain (p = 0.081)
and total score (p = 0.080).
On day 3, no signiﬁcant difference was observed between the
placebo and glycine treatment groups.
Performance test
The results of the test on day 1 and day 3 were shown in Figures 1
and 2, respectively, and statistical analysis of the test on day 1 and
day 3 were shown in Table 2. In the psychomotor vigilance test,
reaction time was signiﬁcantly decreased in glycine group on both
BA
DC
FE
HG
FIGURE 1 | Performance test on day 1. Closed and opened symbols reveal
glycine and placebo ingested group, respectively. Asterisk shows signiﬁcant
differences between glycine and placebo groups. Simple reaction test (A,B),
memory recognition test (E,F) and number addition test (G,H) showed no
signiﬁcance. Psychomotor vigilance test showed signiﬁcant effects in reaction
time (D), however that of correct response did not showed signiﬁcance (C).
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FIGURE 2 | Performance test on day 3. Closed and opened symbols reveal
glycine and placebo ingested group, respectively. Asterisk shows signiﬁcant
differences between glycine and placebo groups. Simple reaction test (A,B),
memory recognition test (E,F) and number addition test (G,H) showed no
signiﬁcance. Psychomotor vigilance test showed signiﬁcant effects in reaction
time (D), however that of correct response did not showed signiﬁcance (C).
day 1 and day 3 (Figures 1D and 2D). While the other tests did
not show signiﬁcant differences, glycine treatment group showed
a tendency toward improvement.
RAT STUDY
Melatonin assay
Plasma melatonin concentrations were not signiﬁcantly different
between the glycine and vehicle treatment groups (Figure 3).
Quantiﬁcation of mRNA expression
The expression of the clock genes Bmal1 and Per2 and the
neuropeptides AVP and VIP in the SCN were measured follow-
ing glycine or vehicle administration. Although Bmal1 and Per1
mRNA expression did not show signiﬁcant differences between
the glycine and vehicle treatment groups (data not shown), AVP
andVIP were signiﬁcantly increased during the light period in the
glycine group (Figures 4A,B).
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Table 2 | Statistical analysis of performance test.
Day 1 Day 3
Treatment Treatment× time Treatment Treatment× time
F 1,6 p F 2,12 p F 1,6 p F 2,12 p
SIMPLE REACTIONTIMETEST
Correct response 1.35 0.289 0.18 0.838. 1.36 0.288 1.4 0.284
Reaction time 3.78 0.1 1.78 0.211 0.02 0.892 1.09 0.369
PSYCHOMOTORVIGILANCETEST
Correct response 2.84 0.143 1.41 0.283 0.4 0.55 0.71 0.513
Reaction time 21.69 0.003 0.66 0.536 6.01 0.05 0.07 0.937
MEMORY RECOGNITIONTEST
Correct response 4.57 0.076 2.65 0.111 1.54 0.261 4.08 0.044
Reaction time 1.7 0.24 1 0.397 0.73 0.426 0.53 0.602
NUMBERADDITIONTEST
Correct response 0.0004 0.984 2.1 0.165 0.55 0.486 0.89 0.435
Reaction time 0.05 0.838 0.19 0.831 0.07 0.795 1.32 0.304
The data are expressed as the mean±SE. A two-way ANOVA was used to test statistical signiﬁcance.
FIGURE 3 | Plasma melatonin concentration. Plasma melatonin
concentration was not changed by glycine administration.
DISCUSSION
Most individuals experience periods of sleep deprivation. In the
ﬁrst half of this study, the ingestion of 3 g of glycine before bed-
time ameliorated daytime fatigue under modest sleep restriction
conditions. These improvements were observed on the ﬁrst day
but not on the third day of three consecutive sleep-restricted days.
Additionally, performance which was evaluated by psychomotor
vigilance test was also improved on both ﬁrst and third days. Thus,
glycine improved subjective parameters, such as fatigue, only on
day 1; however, objective parameters, such as psychomotor vig-
ilance, were improved on both days 1 and 3. The reason for
the continued improvement in psychomotor vigilance until day
3 is not clear, and further study is needed on the improvement
of both subjective and objective parameters by glycine inges-
tion. Our results indicate that the ingestion of glycine at bedtime
occasionally improves the impairments in subjective alertness and
neurobehavioral functions induced by acute and modest sleep
restriction.
Previously, we showed the effects of glycine on sleep quality
in humans who had continuously complained about their sleep
quality (Inagawa et al., 2006a,b; Yamadera et al., 2007). In these
studies, ingestion of 3 g glycine was found to improve subjective
sleep quality (Inagawa et al., 2006a) and shorten sleep latency
(Yamadera et al., 2007) as measured by polysomnography. In the
current study, the participants had no sleep complaints, and the
average of their PSQI scores was 4.7. These scores indicate that
the participants had objectively normal sleep. Sleep was restricted
to 25% less than usual for three consecutive days (i.e., the normal
TIB for our participants was 7.3 h, and the average TIB during the
experiment was 5.5 h). For most individuals, this decrease in sleep
time occurs occasionally in normal life. Recent studies have indi-
cated that consecutive days of partial sleep restriction could induce
adverse effects on subjective sleepiness and neurobehavioral func-
tions similar to those induced by total sleep deprivation (Belenky
et al., 2003; Van Dongen et al., 2003; Vgontzas et al., 2004). In
our experiment, we intended to induce these adverse effects in our
subjects. Glycine signiﬁcantly improved feelings of fatigue com-
paredwith the placebo and showed a tendency to reduce sleepiness
(Table 1) and signiﬁcant improvement in performance (Figures 1
and 2; Table 2). These results indicate that glycine improves sleep
quality not only in people suffering from light insomnia but also
in those with occasional sleep restrictions.
We previously described the pharmacokinetics of orally admin-
istered glycine in rats (Kawai et al., 2012). Gavage injection
of glycine was found to increase both the plasma and cere-
brospinal ﬂuid levels of glycine and to passively diffuse across
the blood–brain barrier via non-speciﬁc transportation. Further-
more,pharmacological ﬁndings showed that glycine primarily acts
on NMDARs in the SCN and decreases the body core temperature
via vasodilatation (Kawai et al., 2009; Bannai and Kawai, 2011).
The relationship between sleep and core body temperature is very
strong. Core body temperature has a circadian oscillation, i.e., it
Frontiers in Neurology | Sleep and Chronobiology April 2012 | Volume 3 | Article 61 | 6
Bannai et al. Effects of glycine on sleep
A
B
FIGURE 4 | Gene expression in the SCN.The expression of AVP (A) and
VIP (B) were signiﬁcantly increased during the light period after glycine
administration.
drops at the onset of sleep (Czeisler et al., 1980; Zulley et al., 1981),
continues to decrease during sleep (Barrett et al., 1993) and grad-
ually rises as a person wakes (Foret et al., 1993). Thus, the heat
dissipation induced by glycine ingestion leads to an improvement
in sleep quality.
Although glycine improves sleep by reducing core body tem-
perature, the effects of glycine on circadian rhythms are still
unknown. Therefore, we investigated the effects of glycine on
plasma melatonin concentration and the mRNA expression of
clock genes and neuropeptides in the SCN. Plasma melatonin
concentration has been shown to be high during the noctur-
nal period, and ingestion of melatonin is known to induce sleep
(Turek and Gillette, 2004; Arendt, 2005). If the plasma melatonin
concentration is indeed increased by glycine ingestion, this phe-
nomenon could be a possible mechanism for sleep improvement
by glycine. We found, however, that the melatonin levels were not
signiﬁcantly changed by gavage glycine administration in either
the diurnal and nocturnal period, suggesting that melatonin is not
related to glycine administration. In addition, we measured the
mRNA expression of known clock genes and neuropeptides in the
SCN. Bmal1 and Per2 are the canonical clock genes expressed in
the SCN (Sakamoto et al., 1998; Oishi et al., 2000; Fahrenkrug
et al., 2008; Dzirbikova et al., 2011). The expression of these genes
was not signiﬁcantly changed by glycine administration, suggest-
ing that glycine does not primarily affect the circadian rhythms.
The expression levels of AVP and VIP in the SCN, however, were
signiﬁcantly increased during the light period (Figures 4A,B). Pre-
viously, the expression levels of these neuropeptides were shown
to oscillate with the circadian rhythm, and expression was shown
to be high at the end of the light period and decreased to low levels
during light period (Ban et al., 1997; Yambe et al., 2002; Kalama-
tianos et al., 2004). Our results showed higher mRNA expression
of both peptides during the light period in control rats; however,
the differences between dark and light expression were very small
in control group. For this experiment, we performed quantitative
RT-PCR, and it is difﬁcult to evaluate small differences in expres-
sion with this method. Glycine increased AVP and VIP expression
4.2- and 3.2-fold, respectively, during the light period. Thus, we
believe that glycine has signiﬁcant effects on the expression levels
of these neuropeptides during the light period. Additionally, there
were no signiﬁcant effects of glycine on bloodAVP concentrations,
blood pressure, or heart rate (data not shown). The localization of
each mRNA is different in the SCN. For instance,VIP is expressed
in the ventrolateral component of the SCN (i.e., the core), AVP
is expressed in the dorsomedial component of the SCN (i.e., the
shell; Moore, 1993). In addition, AVP and VIP are known to inter-
act each other in the SCN (Tamada et al., 1998). The SCN has an
afferent projection to the medial preoptic area (mPOA; Deurveil-
her et al., 2002), an area known to be involved in thermoregulation
(Kumar et al., 2007). Thus, glycine may modulate SCN function
and neurotransmission to the mPOA via the regulation of AVP
and VIP expression.
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